Search Results

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.

Enanta Pharmaceuticals, Inc. today announced that data from the company’s SPRINT study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

Sapphiros is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.